5.49
前日終値:
$5.12
開ける:
$4.98
24時間の取引高:
2.75M
Relative Volume:
2.38
時価総額:
$356.54M
収益:
-
当期純損益:
$-297.11M
株価収益率:
-1.0578
EPS:
-5.19
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
-14.49%
1か月 パフォーマンス:
-0.54%
6か月 パフォーマンス:
-67.24%
1年 パフォーマンス:
-43.98%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PHAT
Phathom Pharmaceuticals Inc
|
5.49 | 356.54M | 0 | -297.11M | -216.95M | -5.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
2024-05-03 | 開始されました | Stifel | Buy |
2024-01-05 | 繰り返されました | Needham | Buy |
2023-08-09 | 開始されました | H.C. Wainwright | Buy |
2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
2023-03-13 | 開始されました | Craig Hallum | Buy |
2022-10-21 | 開始されました | Jefferies | Buy |
2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
2021-05-12 | アップグレード | Goldman | Sell → Neutral |
2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
2021-02-02 | 開始されました | Guggenheim | Buy |
2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
2019-11-20 | 開始されました | Evercore ISI | Outperform |
2019-11-19 | 開始されました | Goldman | Neutral |
2019-11-19 | 開始されました | Jefferies | Buy |
2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Critical Analysis: Quoin Pharmaceuticals (NASDAQ:QNRX) & Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
When (PHAT) Moves Investors should Listen - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - biocentury.com
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom's New CEO Stakes Future on Stock Price and Revenue Goals - Stock Titan
Phathom Pharmaceuticals Announces Leadership Transition in 2025 - TipRanks
Phathom Pharmaceuticals Announces Leadership Succession - MarketScreener
Phathom Pharmaceuticals appoints new CEO - Investing.com
Strategic CEO Change: Phathom Taps Commercial Expert to Drive VOQUEZNA Market Expansion - Stock Titan
Kenan Thompson partners with Phathom for GERD treatment By Investing.com - Investing.com Philippines
Kenan Thompson partners with Phathom for GERD treatment - Investing.com India
Actor and Comedian Kenan Thompson Teams Up with Phathom - GlobeNewswire
Virtu Financial LLC Acquires New Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Raymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Charles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Bank of New York Mellon Corp Purchases 4,557 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Jefferies cuts Phathom Pharmaceuticals target to $13 By Investing.com - Investing.com UK
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating - MarketScreener
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from Brokerages - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com Australia
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St
Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms “Buy” Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - The AM Reporter
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at Needham & Company LLC - The AM Reporter
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks
Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum - TipRanks
H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com
Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance
Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks
Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks
Stifel maintains Buy on Phathom stock with $28 target - Investing.com India
Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa
Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):